Let’s Fight Bladder Cancer, Scotland! @BladderCancerUK @NHS_Lothian @NHS_HS #BladderCancer #BladderCancerAware

That’s a wrap on #UrothelialCancerUpdate2026 in Turin! 🎓 ​Sincere thanks to our chairs, faculty, and attendees for the insightful debates and clinical updates pushing the field forward. ​Thank you for joining us! 👏

Brilliant talk on molecular markers in #bladdercancer by @ParamMariappan at #urothelialcancerupdate2026 meets the #eauguidelines. Lead by Prof @paolo_gontero and @francescosoria The take home messages summarises perfectly the nowadays situation.

With EV+pembrolizumab broadly effective, do we now need biomarkers to identify who benefits most, or who can safely receive less? The key question is no longer only “who is high risk?” but “who still has disease?” ctDNA may help move bladder cancer from static risk groups toward real-time treatment decisions. Excellent presentation by @PGrivasMDPhD at #IUCS26 @neerajaiims @gbanna74 @Sebastiano_Buti @CinziaConted @dralishadamani @nataliagandur @amg120395 @ravikanesvaran @koshkin85 @MicheleMaffezz @ManiamAkash @ParamMariappan @dmukherji @VanitaNoronha @montypal @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @yekeduz_emre @ONCOassist

Fantastic meeting #IUCS26 @urologysummit led by @gbanna74 @ravikanesvaran international colleagues, great speakers @montypal @neerajaiims @DrYukselUrun @dr__mukherji @ProfSyedHussain @ParamMariappan @JimCatto @nataliagandur @OncoAlert @IBCG_BladderCA @BladderCancerUS @koshkin85

✨️Precision Oncology through Biomarkers: Assessing What Matters Most — Prostate Deborah Mukherji @dmukherji at #IUCS26✨️ 🔵 PCWG4 proposes moving beyond the simple “hormone-sensitive/castration-resistant” labels toward an androgen-pathway modulation continuum: APM-naïve, APM-sensitive and APM-resistant disease. 🔵 Precision oncology must remain patient-centred: living longer matters, but so do quality of life, independence, toxicity, time with family, financial security and sustainable access to treatment. 🔵 A major real-world gap persists: in data from almost 70,000 men with mHSPC, ADT monotherapy remained >50% by 2020 despite strong evidence supporting treatment intensification. 🔵 Treatment selection in mHSPC/APMS should integrate disease biology + patient preferences + symptoms + comorbidities + access — identifying who may benefit from de-escalation versus early intensification. 🔵 Biomarkers should answer clinically relevant questions: • baseline risk • genomic classifiers • germline susceptibility • actionable alterations • PSMA imaging phenotype • evolving tumour biology with ctDNA/CTCs 🔵 In low-volume/oligometastatic HSPC, decisions remain individualized: primary RT, ADT + ARPI and selected intensification strategies, while ADT alone is increasingly difficult to justify. 🔵 ctDNA adds dynamic prognostic information: ctDNA positivity combined with higher PSA identifies particularly poor prognosis, whereas very low PSA with ctDNA negativity identifies a more favorable group. 🔵 The key message: test with purpose, integrate intelligently, act on what matters, and reassess over time. @neerajaiims @gbanna74 @Sebastiano_Buti @CinziaConted @dralishadamani @nataliagandur @amg120395 @PGrivasMDPhD @ravikanesvaran @koshkin85 @MicheleMaffezz @ManiamAkash @ParamMariappan @VanitaNoronha @montypal @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @DrYukselUrun @yekeduz_emre @myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb #ProstateCancer #pcsm #GUOncology #PrecisionOncology #Biomarkers

✨️ Precision Oncology through Biomarkers: Assessing What Matters Most — Bladder Syed A. Hussain at #IUCS26✨️ 🟠 Urothelial cancer is highly heterogeneous, not only molecularly but also histologically — and variant histologies may still be underreported in routine practice. 🟠 The treatment landscape has changed dramatically: EV + pembrolizumab in EV-302 produced a major improvement in both OS and PFS versus chemotherapy, establishing a new benchmark in first-line advanced urothelial cancer. 🟠 But the unmet need remains substantial: • ~50% of patients progress within the first 12 months • ~10% show primary resistance • many others eventually develop acquired resistance • toxicity can also limit continued EV exposure 🟠 This makes resistance biology a central question. Potential mechanisms of ADC resistance are likely multifactorial and may involve: • instability before the ADC reaches the tumor • impaired internalisation • loss or alteration of the target antigen • epitope masking/mutation • lysosomal dysfunction • drug-efflux mechanisms • intrinsic resistance to the payload 🟠 UC expresses multiple potentially actionable targets, including NECTIN-4, TROP-2, HER2 and FGFR alterations, creating opportunities for increasingly biomarker-informed sequencing. 🟠 Importantly, NECTIN-4 expression is not uniform across histologic variants, reinforcing the need to understand tumor subtype and target biology rather than assuming one biomarker fits all urothelial cancers. 🟠 For immunotherapy, candidate biomarkers such as PD-L1, TMB, CD8+ TILs/IFNγ and TGFβ may capture different aspects of the tumor immune continuum — from inflamed to immune-excluded to immune-desert disease. 🟠 Clinical takeaway: precision oncology in bladder cancer is moving beyond simply asking “Is the target present?” toward asking which target matters, in which tumor subtype, at which point in the disease, and how resistance evolves under treatment. @neerajaiims @gbanna74 @Sebastiano_Buti @CinziaConted @dralishadamani @nataliagandur @amg120395 @PGrivasMDPhD @ravikanesvaran @koshkin85 @MicheleMaffezz @ManiamAkash @ParamMariappan @dmukherji @VanitaNoronha @montypal @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @DrYukselUrun @yekeduz_emre @myESMO @ASCO @ASCOPost @AmerUrological @urotoday @UrologyTimes @OncLive @ecancer @Uroweb #BladderCancer #blcsm #GUOncology #PrecisionOncology #ADC #Biomarkers #UroOnc

Major breakthroughs in localized & metastatic #bladdercancer bring longer survival & better cure chances, with biomarkers guiding future trials. Join us at #IUCS26 with @PGrivasMDPhD, in person or virtually! Register for free 🧷 ow.ly/9U6L50YFwfP #IUCS #Oncology

Welcome by chairs 👏🏾

🚨 Tomorrow, #IUCS26 begins in Guildford 🇬🇧 Two days built around the questions shaping contemporary GU oncology: 🧬 Which biomarkers are truly ready to guide treatment? 🔄 How should local and systemic therapies be integrated? 🧩 How should we approach variant histologies? 👥 How do frailty, toxicity and vulnerability change our decisions? 🔬 What can emerging and real-world research teach us? 💬 And how do we translate all of this into everyday clinical practice? Join an international faculty across prostate, bladder, kidney, testicular and rare GU cancers. 📍 Guildford, UK 📅 3–4 September 2026 💻 In person + virtual 🎟️ Registration is FREE: webplatform.planning.it/IUCS… @neerajaiims @gbanna74 @Sebastiano_Buti @CinziaConted @dralishadamani @nataliagandur @amg120395 @PGrivasMDPhD @ravikanesvaran @koshkin85 @MicheleMaffezz @ManiamAkash @ParamMariappan @dmukherji @VanitaNoronha @montypal @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @DrYukselUrun @yekeduz_emre #IUCS26 #GUOncology #UroOnc #ProstateCancer #BladderCancer #KidneyCancer #PrecisionOncology #CancerResearch

Real world update my new name Parminderakis singh by Petros

Honored that our @IBCG_BladderCA consensus paper on "Optimal management of muscle-invasive bladder cancer" has received the @EUplatinum Impact Award as the most influential work in its June 2026 issue! Especially meaningful to see the 🌎 impact of this work, bringing together multidisciplinary expertise to help guide evidence-based care, treatment sequencing, and the next generation of clinical trials for patients with MIBC worldwide. Grateful to our co-authors, IBCG colleagues, and @UroDocAsh for his vision and commitment to improving bladder cancer outcomes. Thank you @Albert0Briganti for this amazing recognition! @CleClinicMD @CleClinicUro @caseccc @EurUrolOncol @Uroweb @WorldBladderCan @FaltasLab @Uromigos @OncoAlert @BladderCancerUS @SpiessPhilippe @GTumors Full paper here👇 doi.org/10.1016/j.eururo.202…

IBCG some new faces and some known @UroDocAsh congratulations for putting together a great meeting @IBCG_BladderCA @FaltasLab @apolo_andrea @

🚨 #IUCS26 is back on Sept 3-4! Join the International Urology Cancer Summit in Guildford (UK) or online 💻 🔬 Top global experts & e-posters 🎓 8 CPD credits (in-person only) 💸 FREE registration 🎟️ Register by Sept 2: urologycancersummit.org/regi… #Urology #Oncology #UroCan

Please consider registering for this amazing meeting hosted by @gbanna74 & @ravikanesvaran! A terrific faculty including @dmukherji, @ProfSyedHussain, @alison_tree, @DrDarrenPoon, @ParamMariappan, @neerajaiims, @PGrivasMDPhD, @koshkin85, @DanieleRaggi83, @VanitaNoronha, @amg120395 & @MariaBarbu128! Always an amazing time w great learning. New this year - oral presentations, one of which will be delivered by my former research fellow @NickSalgia @RoswellPark!

Join us in this incredible meeting in England organized by @gbanna74 @ravikanesvaran & a great team with stellar faculty, sessions, networking! I joined last year & was impressed with the quality! @ParamMariappan @montypal @neerajaiims @alison_tree @dmukherji @ProfSyedHussain

We are on a roll. We have opened our 12th site. Welcome to NHS Lothian - Western General Hospital, Edinburgh. You are going to smash recruitment. Good luck. @ParamMariappan @NHS_Lothian @CombatCancer @LeicesterCTU @trlgriffiths

Which is exactly why we at @IBCG_BladderCA [and @sitcancer] have maintained that TaHG should be classified as high risk. Because the clinical outcomes, molecular biology, progression patterns, all point in the same direction. High-grade biology matters more than arbitrary cutoffs; a TaHG tumor does not suddenly become biologically “intermediate risk” because it is 2.95 cm versus 3.02 cm Classification is not semantics. Classification drives treatment. And treatment drives outcomes. @BladderCancerUS @WorldBladderCan

Manchester #radbio represented at #ESTRO26 with honorary biologist @janeshortall1- the red T-shirts are special! @RT_physics @ESTRO_RT #BioCommittee @MCRCnews

Another great day out in #Edinburgh! Marking our 8th #BCAM walk with the first ever BCAM Spacehopper race 😃 Many thanks to all who attended. (Photos/video shared with permission) @BladderCancerUK @ScotParl @WorldBladderCan #BladderCancerAwareness

I’m helping raise money for Rosemere Cancer Foundation! Support me at: justgiving.com/page/alison-b… NOT TOO LATE TO DONATE. ALL MONEY TO @RosemereCF supporting patients across #lancs #southcumbria #walkingforjohn #walkingformypatients